These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 11409153)

  • 1. Disease controlling antirheumatic therapy in spondyloarthropathy.
    Dougados M
    J Rheumatol Suppl; 2001 Jun; 62():16-20. PubMed ID: 11409153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacotherapy for spondyloarthropathies].
    Babić-Naglić D
    Reumatizam; 2004; 51(2):22-8. PubMed ID: 15554373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab.
    Brandt J; Haibel H; Reddig J; Sieper J; Braun J
    J Rheumatol; 2002 Jan; 29(1):118-22. PubMed ID: 11824947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis.
    Maksymowych WP; Inman RD; Gladman D; Thomson G; Stone M; Karsh J; Russell AS;
    J Rheumatol; 2003 Jun; 30(6):1356-63. PubMed ID: 12784417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy.
    De Rycke L; Vandooren B; Kruithof E; De Keyser F; Veys EM; Baeten D
    Arthritis Rheum; 2005 Jul; 52(7):2146-58. PubMed ID: 15986373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations.
    Generini S; Giacomelli R; Fedi R; Fulminis A; Pignone A; Frieri G; Del Rosso A; Viscido A; Galletti B; Fazzi M; Tonelli F; Matucci-Cerinic M
    Ann Rheum Dis; 2004 Dec; 63(12):1664-9. PubMed ID: 15297279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy.
    Van Den Bosch F; Kruithof E; Baeten D; Herssens A; de Keyser F; Mielants H; Veys EM
    Arthritis Rheum; 2002 Mar; 46(3):755-65. PubMed ID: 11920412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological therapies in the spondyloarthritides--the current state.
    Braun J; Sieper J
    Rheumatology (Oxford); 2004 Sep; 43(9):1072-84. PubMed ID: 15187239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy.
    Tse SM; Burgos-Vargas R; Laxer RM
    Arthritis Rheum; 2005 Jul; 52(7):2103-8. PubMed ID: 15986366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab.
    Schatteman L; Gyselbrecht L; De Clercq L; Mielants H
    J Rheumatol; 2006 Jan; 33(1):82-5. PubMed ID: 16292792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intestines and joints: an entity?].
    De Vos M
    Verh K Acad Geneeskd Belg; 2002; 64(2):85-99; discussion 99-104. PubMed ID: 12085568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of intra-articular infliximab on synovial membrane pathology in a patient with a seronegative spondyloarthropathy.
    Ahern MJ; Campbell DG; Weedon H; Papangelis V; Smith MD
    Ann Rheum Dis; 2008 Sep; 67(9):1339-42. PubMed ID: 18408247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment.
    Briot K; Gossec L; Kolta S; Dougados M; Roux C
    J Rheumatol; 2008 May; 35(5):855-61. PubMed ID: 18381782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy.
    Akkoc N; van der Linden S; Khan MA
    Best Pract Res Clin Rheumatol; 2006 Jun; 20(3):539-57. PubMed ID: 16777581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicentre study.
    Collantes-Estevez E; Muñoz-Villanueva MC; Zarco P; Torre-Alonso JC; Gratacós J; González C; Sanmartí R; Cañete JD;
    Rheumatology (Oxford); 2005 Dec; 44(12):1555-8. PubMed ID: 16118228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy.
    Kruithof E; Baeten D; Van den Bosch F; Mielants H; Veys EM; De Keyser F
    Ann Rheum Dis; 2005 Apr; 64(4):529-36. PubMed ID: 15388510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Similarities and differences between spondyloarthritis in Asia and other parts of the world.
    Zhang S; Li Y; Deng X; Huang F
    Curr Opin Rheumatol; 2011 Jul; 23(4):334-8. PubMed ID: 21494185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spondyloarthropathy for practicing rheumatologists: diagnosis, indication for disease-controlling antirheumatic therapy, and evaluation of the response.
    Miceli-Richard C; van der Heijde D; Dougados M
    Rheum Dis Clin North Am; 2003 Aug; 29(3):449-62. PubMed ID: 12951861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Ankylosing spondylitis--the current situation and new therapeutic options].
    Zlnay D; Zlnay M; Rovenský J
    Vnitr Lek; 2006; 52(7-8):730-5. PubMed ID: 16967616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of ankylosing spondylitis.
    Clegg DO
    J Rheumatol Suppl; 2006 Sep; 78():24-31. PubMed ID: 17042057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.